News Conference News CRT 2026 AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis L.A. McKeown March 11, 2026
News Daily News Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI Yael L. Maxwell December 29, 2025
News Daily News Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News Todd Neale December 26, 2025
News Conference News TCT 2025 At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I Yael L. Maxwell November 07, 2025
News Conference News ESC 2025 Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD L.A. McKeown September 05, 2025
News Conference News CX Symposium 2025 Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices L.A. McKeown April 23, 2025
News Conference News VIVA 2024 Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK L.A. McKeown November 05, 2024
News Conference News TCT 2024 DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF Caitlin E. Cox October 28, 2024
News Conference News ESC 2024 REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD Todd Neale September 09, 2024
News Daily News DES Best for In-Stent Restenosis, but DCBs Also Viable Michael O'Riordan August 13, 2024
News Conference News EuroPCR 2024 PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3 Yael L. Maxwell May 17, 2024
News Conference News CRT 2024 Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries L.A. McKeown March 14, 2024
News Conference News TCT 2023 Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis Todd Neale November 02, 2023
News Conference News TCT 2023 LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI L.A. McKeown October 25, 2023
News Conference News TCT 2023 Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door? L.A. McKeown October 24, 2023
News Daily News Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry Todd Neale October 16, 2023
News Conference News LINC 2023 PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD L.A. McKeown June 21, 2023